Vanda Pharmaceuticals Financial Statements (VNDA)
|
|
|
|
Report date
|
|
|
24.02.2022 |
09.02.2023 |
08.02.2024 |
14.02.2025 |
12.02.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
268.7 |
254.4 |
192.6 |
198.8 |
216.1 |
|
216.9 |
|
Operating Income, bln rub |
|
|
42.2 |
6.33 |
-14.0 |
-40.7 |
-151.2 |
|
-172.1 |
|
EBITDA, bln rub |
? |
|
45.0 |
9.06 |
-10.9 |
-32.5 |
-139.3 |
|
-160.6 |
|
Net profit, bln rub |
? |
|
33.2 |
6.28 |
2.51 |
-18.9 |
-220.5 |
|
-260.9 |
|
|
OCF, bln rub |
? |
|
64.2 |
32.0 |
12.8 |
-15.8 |
-109.4 |
|
-111.3 |
|
CAPEX, bln rub |
? |
|
0.552 |
0.679 |
0.383 |
0.490 |
0.998 |
|
0.484 |
|
FCF, bln rub |
? |
|
63.7 |
31.3 |
12.4 |
-16.2 |
-110.4 |
|
-111.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
200.9 |
223.8 |
191.8 |
228.1 |
354.2 |
|
377.1 |
|
Cost of production, bln rub |
|
|
25.6 |
24.3 |
14.8 |
11.3 |
13.0 |
|
11.9 |
|
R&D, bln rub |
|
|
75.4 |
85.8 |
76.8 |
74.4 |
109.3 |
|
108.4 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
593.8 |
634.2 |
648.4 |
656.2 |
488.9 |
|
433.5 |
|
Net Assets, bln rub |
? |
|
504.9 |
527.2 |
544.9 |
538.5 |
327.2 |
|
280.8 |
|
Debt, bln rub |
|
|
12.4 |
11.1 |
9.40 |
12.4 |
12.6 |
|
13.1 |
|
Cash, bln rub |
|
|
432.8 |
466.9 |
388.3 |
374.6 |
263.8 |
|
202.3 |
|
Net debt, bln rub |
|
|
-420.4 |
-455.7 |
-378.9 |
-362.3 |
-251.2 |
|
-189.2 |
|
|
Ordinary share price, rub |
|
|
15.7 |
7.39 |
4.22 |
4.79 |
8.82 |
|
6.39 |
|
Number of ordinary shares, mln |
|
|
55.5 |
56.5 |
57.4 |
58.1 |
58.9 |
|
59.5 |
|
|
Market cap, bln rub |
|
|
872 |
417 |
242 |
279 |
520 |
|
380 |
|
EV, bln rub |
? |
|
451 |
-38 |
-137 |
-84 |
269 |
|
191 |
|
Book value, bln rub |
|
|
485 |
509 |
424 |
424 |
210 |
|
166 |
|
|
EPS, rub |
? |
|
0.60 |
0.11 |
0.04 |
-0.33 |
-3.74 |
|
-4.39 |
|
FCF/share, rub |
|
|
1.15 |
0.55 |
0.22 |
-0.28 |
-1.87 |
|
-1.88 |
|
BV/share, rub |
|
|
8.73 |
9.01 |
7.38 |
7.30 |
3.57 |
|
2.79 |
|
|
EBITDA margin, % |
? |
|
16.8% |
3.56% |
-5.68% |
-16.4% |
-64.4% |
|
-74.1% |
|
Net margin, % |
? |
|
12.3% |
2.47% |
1.30% |
-9.51% |
-102.0% |
|
-120.3% |
|
FCF yield, % |
? |
|
7.30% |
7.50% |
5.13% |
-5.83% |
-21.2% |
|
-29.4% |
|
ROE, % |
? |
|
6.57% |
1.19% |
0.46% |
-3.51% |
-67.4% |
|
-92.9% |
|
ROA, % |
? |
|
5.58% |
0.99% |
0.39% |
-2.88% |
-45.1% |
|
-60.2% |
|
|
P/E |
? |
|
26.3 |
66.5 |
96.5 |
-14.7 |
-2.36 |
|
-1.46 |
|
P/FCF |
|
|
13.7 |
13.3 |
19.5 |
-17.1 |
-4.71 |
|
-3.40 |
|
P/S |
? |
|
3.24 |
1.64 |
1.26 |
1.40 |
2.41 |
|
1.75 |
|
P/BV |
? |
|
1.80 |
0.82 |
0.57 |
0.66 |
2.47 |
|
2.29 |
|
EV/EBITDA |
? |
|
10.0 |
-4.24 |
12.5 |
2.57 |
-1.93 |
|
-1.19 |
|
Debt/EBITDA |
|
|
-9.34 |
-50.3 |
34.6 |
11.1 |
1.80 |
|
1.18 |
|
|
R&D/CAPEX, % |
|
|
13 653% |
12 632% |
20 058% |
15 190% |
10 949% |
|
22 405% |
|
|
CAPEX/Revenue, % |
|
|
0.21% |
0.27% |
0.20% |
0.25% |
0.46% |
|
0.22% |
|
| Vanda Pharmaceuticals shareholders |
